Britain and America have hammered out a major trade agreement that will preserve no levies on UK drug exports entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost spending on medicines through the National Health Service (NHS). This pledge guarantees that duties on these vital goods will stay at zero for a duration of 36 months.
This deal is in response to earlier statements to dramatically increase import taxes on branded drug imports, with figures mentioned up to one hundred percent.
"This arrangement between the Britain bolsters the international landscape for cutting-edge drugs and brings much-needed fairness to American-British medicine commerce," a release noted.
Commercial Impact
Medicines represent one of the UK's largest export categories to the United States, which is by far the largest market for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period leading up to last September, the UK exported pharmaceutical products valued at billions to the US. This value accounted for a significant portion of British export trade in that span.
"This guarantee protects jobs, stimulates funding and facilitates the UK to become a international leader for life sciences," a minister remarked.
Detailed NHS Changes
The pact involves several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to raise overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be restricted at fifteen percent. Previously, repayments exceeded twenty percent.
Broader Context
The deal follows a long-running row between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were heightened by assertions that US consumers were paying significantly more for the same drugs than consumers in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward projects in the United States.
One official publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
